Welcome to the era of mindful medicine.
The Latest From The Lab:
Psilera receives positive preclinical in vivo data for frontotemporal dementia (FTD) candidate, PSIL-006.
Read the full press release here!
Psilera
At A
Glance
-
We have created and developed six separate serotonergic compound families.
-
Two patents have been issued from the USPTO covering over 1 million novel compounds. Several more patents expected by 1H 2024.
-
The Psilera leadership team has over 100 years of combined experience in the biotech and pharmaceutical industries.
-
Our best-in-class proprietary compound library has coverage for over 1 million novel compounds.
-
Psilera’s co-founders bring over $1.5B in cumulative value created from prior start-ups.
Psilera is revolutionizing how small molecule drug discovery is done, giving rise to more patient-centric therapy options for those suffering from neurological conditions.
Based on the current pipeline, our focus is on hard-to-treat disorders, many of which have no currently available treatments, such as Frontotemporal Dementia (FTD).
UPCOMING EVENTS
UPCOMING EVENTS
January 12
San Francisco, CA
Sachs: Neuroscience Innovation Forum
Co-Founders Chris Witowski, PhD and Jackie von Salm, PhD will be on the West Coast for the 8th Annual Sachs Neuroscience Innovation Forum. Dr. Witowski will be giving a presentation highlight the research successes accomplished by the team in 2024 and the initiatives of Psilera in 2025. While in San Francisco, the leadership team will be meeting with industry leaders and colleagues to discuss licensing and research projects. If you would like to connect with our founders please contact info@psilera.com to arrange a time.